• Molecular NameRetapamulin
  • SynonymRetapamulin
  • Weight517.775
  • Drugbank_IDDB01256
  • ACS_NO224452-66-8
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)6.63
  • pkaN/A
  • LogD (pH=7, predicted)4.33
  • Solubility (experiment)0.07 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-1.24
  • LogSw (predicted, AB/LogsW2.0)0.06
  • Sw (mg/ml) (predicted, ACD/Labs)0.12
  • No.of HBond Donors1
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds6
  • TPSA92.14
  • StatusFDA approved
  • AdministrationTopical (ointment)
  • PharmacologyA topical antibiotic developed by GlaxoSmithKline.
  • Absorption_valueN/A
  • Absorption (description)emic exposure following topical application of retapamulin through intact and abraded skin was low.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding94.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmIn vitro studies with human liver microsomes demonstrated that retapamulin is extensively metabolized to numerous metabolites, of which the predominant routes of metabolism were mono-oxygenation and N-demethylation. The major enzyme responsible for metabolism of retapamulin in human liver microsomes was cytochrome P450 3A4 (CYP3A4).
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThe adverse events reported in more than 1% of patients who received Retapamulin include headache, application site irritation, diarrhea, nausea, nasopharyngitis, elevated serum creatinine phosphokinase, eczema, pyrexia.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A